Phase 3
Completed N=220
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
Psoriasis
Source: ClinicalTrials.gov NCT04167462 ↗
Enrolled (actual)
220
Serious AEs
2.4%
Results posted
Nov 2022
Primary outcomePrimary: The Percentage of Participants With sPGA Response of 0 or 1 — 55.6; 6.8 Percentage of participants — p=<0.0001
◆ Published Evidence
Emerging
3citations · ~3 / year
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
Linked Publications
-
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Percentage of Participants With sPGA Response of 0 or 1 |
55.6; 6.8 | <0.0001 sig |
| PRIMARY The Percentage of Participants With PASI 75 Response |
68.8; 8.1 | <0.0001 sig |
| SECONDARY The Percentage of Participants With PASI 90 Response |
38.2; 1.4 | <0.0001 sig |
| SECONDARY The Percentage of Participants With PASI 100 Response |
4.2; 0 | — |
| SECONDARY The Percentage of Participants With sPGA 0 Response |
13.9; 0 | — |
| SECONDARY Change From Baseline in PSSD Symptom Score |
-29.4; -1.8 | — |
| SECONDARY The Percentage of Participants With Ss-PGA Score of 0 or 1 |
62.9; 9.8 | <0.0001 sig |
| SECONDARY The Percentage of Participants With DLQI Score of 0 or 1 |
36.4; 11.6 | <0.0001 sig |
| SECONDARY The Percentage of Participants With PGA-F Score of 0 or 1 |
19.6; 4.2 | 0.0947 |
| SECONDARY The Percentage of Participants With PSSD Symptom Score of 0 |
4.9; 1.4 | 0.1741 |
| SECONDARY The Percentage of Participants With Pp-PGA Score of 0 or 1 |
66.7; 0 | — |
| SECONDARY The Percentage of Participants With PASI 75 Response at Week 52 |
71.0; 70.3 | — |
| SECONDARY The Percentage of Participants With sPGA Response of 0 or 1 at Week 52 |
51.0; 52.7 | — |
Eligibility Criteria
Inclusion Criteria
- Plaque psoriasis for at least 6 months
- Moderate to severe disease
- Candidate for phototherapy or systemic therapy
Exclusion Criteria
- Other forms of psoriasis
- History of recent infection
- Prior exposure to BMS-986165
Other inclusion/exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT04167462) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.